Duloxetine API Market Research Report Information: by Application (Major Depressive Disorder, Generalized Anxiety Disorder (GAD), Fibromyalgia, Neuropathic Pain, Chronic Musculoskeletal Pain), by Region (Americas, Europe, Asia-Pacific, Others) - Forecast till 2032

1 Executive Summary

2 Market Introduction

2.1 Definition 14

2.2 Scope of the Study 14

2.3 Market Structure 14

3 Research Methodology

3.1 Research Process 15

3.2 Primary Research 16

3.3 Secondary Research 17

3.4 Market Size Estimation 18

3.5 Forecast Model 18

4 Market Dynamics

4.1 Overview 19

4.2 Drivers 19

4.2.1 Rising Rates of Anxiety Cases 19

4.2.2 Increasing Prevalence Rates of Depression 20

4.2.3 Increasing Penetration of Generic Versions of Drugs 20

4.2.4 Strong Drug Pipeline 20

4.2.5 Growing Demand for Newly Developed Small Molecule Drugs 20

4.2.6 Growing Trend of Outsourcing 20

4.3 Restraints 21

4.3.1 Changing Economic Conditions in Different Regions 21

4.3.2 Side-Effects of Duloxetine 21

4.4 Opportunities 22

4.4.1 Advancements in API Manufacturing 22

4.4.2 Patent Expiry Creating Opportunities for Generic and API Manufacturers 22

5 Market Factor Analysis

5.1 Value Chain Analysis 23

5.1.1 Overview 23

5.1.2 R&D 23

5.1.3 Procurement of Raw Material 23

5.1.4 Manufacturing 24

5.1.5 Distribution & Sales 24

5.1.6 Post-Sales Monitoring 24

5.2 Porter’s Five Forces Model 25

5.2.1 Overview 25

5.2.2 Threat of New Entrants 25

5.2.3 Bargaining Power of Suppliers 26

5.2.4 Threat of Substitutes 26

5.2.5 Bargaining Power of Buyers 26

5.2.6 Intensity of Rivalry 26

5.3 Regulatory Scenario 27

5.3.1 Overview 27

5.3.2 Registration of API in the US 27

5.3.3 Registration of API in the European Union (EU) 27

5.3.4 Comparison of Requirements for the Registration of API in the US and EU 28

5.4 Specifications 29

5.5 Pricing Evolution 30

5.6 Patent Analysis 31

5.7 Product Pipeline Analysis 33

5.7.1 Overview 33

5.7.2 Duloxetine (Cymbalta) for Dysthymic Disorder and Depressive Disorder NOS 33

5.7.3 Effect of Combined Morphine and Duloxetine on Chronic Pain 33

5.7.4 Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients with Chronic Pain 34

5.7.5 Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents with Depressive Disorder 34

5.7.6 Perioperative Duloxetine for Pain Management After Laparoscopic Hysterectomy 34

6 Global Duloxetine API Market by Application

6.1 Overview 35

6.2 Major Depressive Disorder 37

6.3 Generalized Anxiety Disorder (GAD) 38

6.4 Fibromyalgia 39

6.5 Neuropathic Pain 40

6.6 Chronic Musculoskeletal Pain 41

6.7 Others 41

7 Global Duloxetine API Market by Region

7.1 Overview 42

7.2 Americas 44

7.2.1 North America 46

7.2.1.1 US 48

7.2.1.2 Canada 49

7.2.2 Latin America 50

7.3 Europe 51

7.3.1 Western Europe 53

7.3.1.1 Germany 55

7.3.1.2 France 56

7.3.1.3 UK 57

7.3.1.4 Italy 57

7.3.1.5 Spain 58

7.3.1.6 Rest of Western Europe 59

7.3.2 Eastern Europe 60

7.4 Asia-Pacific 61

7.4.1 China 63

7.4.2 India 64

7.4.3 Japan 65

7.4.4 Rest of Asia-Pacific 66

7.5 Middle East & Africa 67

7.5.1 Middle East 69

7.5.2 Africa 70

8 Competitive Landscape

8.1 Overview 71

8.2 Company Ranking Analysis 71

9 Company Profiles

9.1 Teva Pharmaceutical Industries Ltd 73

9.1.1 Company Overview 73

9.1.2 Financial Overview 73

9.1.3 Products/Services Offered 74

9.1.4 Key Developments 74

9.1.5 SWOT Analysis 74

9.1.6 Key Strategies 75

9.2 Sun Pharmaceutical Industries Ltd 76

9.2.1 Company Overview 76

9.2.2 Financial Overview 76

9.2.3 Products/Services Offered 76

9.2.4 Key Developments 77

9.2.5 SWOT Analysis 78

9.2.6 Key Strategies 78

9.3 Aurobindo Pharma 79

9.3.1 Company Overview 79

9.3.2 Financial Overview 79

9.3.3 Products/Services Offered 79

9.3.4 Key Developments 80

9.3.5 SWOT Analysis 80

9.3.6 Key Strategies 81

9.4 Lupin 82

9.4.1 Company Overview 82

9.4.2 Financial Overview 82

9.4.3 Products/Services Offered 83

9.4.4 Key Developments 83

9.4.5 SWOT Analysis 84

9.4.6 Key Strategies 84

9.5 Zydus Cadila 85

9.5.1 Company Overview 85

9.5.2 Financial Overview 85

9.5.3 Products/Services Offered 86

9.5.4 Key Developments 86

9.5.5 SWOT Analysis 86

9.5.6 Key Strategies 86

9.6 Eli Lilly and Company 87

9.6.1 Company Overview 87

9.6.2 Financial Overview 87

9.6.3 Products Offering 88

9.6.4 Key Developments 88

9.6.5 SWOT Analysis 88

9.6.6 Key Strategies 88

9.7 Shodhana Laboratories 89

9.7.1 Company Overview 89

9.7.2 Financial Overview 89

9.7.3 Products/Services Offered 89

9.7.4 Key Developments 89

9.7.5 SWOT Analysis 90

9.7.6 Key Strategies 90

9.8 Hetero 91

9.8.1 Company Overview 91

9.8.2 Financial Overview 91

9.8.3 Products/Services Offered 91

9.8.4 Key Developments 91

9.8.5 SWOT Analysis 92

9.8.6 Key Strategies 92

9.9 Apotex Inc. 93

9.9.1 Company Overview 93

9.9.2 Financial Overview 93

9.9.3 Products/Services Offered 93

9.9.4 Key Developments 93

9.9.5 SWOT Analysis 94

9.9.6 Key Strategies 94

9.10 Shionogi Inc. 95

9.10.1 Company Overview 95

9.10.2 Financial Overview 95

9.10.3 Products/Services Offered 95

9.10.4 Key Developments 95

9.10.5 SWOT Analysis 96

9.10.6 Key Strategies 96

9.11 Zhejiang Huahai Pharmaceutical Co., Ltd 97

9.11.1 Company Overview 97

9.11.2 Financial Overview 97

9.11.3 Products/Services Offered 98

9.11.4 Key Developments 98

9.11.5 SWOT Analysis 98

9.11.6 Key Strategies 98

10 Appendix

10.1 References 99

10.2 Related Reports 99

11 List of Tables

TABLE 1 DIFFERENCES IN THE API REGISTRATION REQUIREMENTS IN THE US AND EU 28

TABLE 2 SPECIFICATIONS FOR DULOXETINE 29

TABLE 3 PRICE RANGE FOR DULOXETINE API (USD/KG) 30

TABLE 4 PATENT ANALYSIS FOR THE GLOBAL DULOXETINE API MARKET 31

TABLE 5 DULOXETINE API MARKET: PRODUCT PIPELINE ANALYSIS 33

TABLE 6 GLOBAL DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 36

TABLE 7 GLOBAL DULOXETINE API MARKET FOR MAJOR DEPRESSIVE DISORDER, BY REGION, 2022-2030 (USD MILLION) 37

TABLE 8 GLOBAL DULOXETINE API MARKET FOR GENERALIZED ANXIETY DISORDER (GAD), BY REGION, 2022-2030 (USD MILLION) 38

TABLE 9 GLOBAL DULOXETINE API MARKET FOR FIBROMYALGIA, BY REGION, 2022-2030 (USD MILLION) 39

TABLE 10 GLOBAL DULOXETINE API MARKET FOR NEUROPATHIC PAIN, BY REGION, 2022-2030 (USD MILLION) 40

TABLE 11 GLOBAL DULOXETINE API MARKET FOR CHRONIC MUSCULOSKELETAL PAIN, BY REGION, 2022-2030 (USD MILLION) 41

TABLE 12 GLOBAL DULOXETINE API MARKET, BY REGION, 2022-2030 (USD MILLION) 43

TABLE 13 GLOBAL DULOXETINE API MARKET VOLUME, BY REGION, 2022-2030 (METRIC TON) 43

TABLE 14 AMERICAS: DULOXETINE API MARKET, BY REGION, 2022-2030 (USD MILLION) 45

TABLE 15 AMERICAS: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 45

TABLE 16 NORTH AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 46

TABLE 17 NORTH AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 47

TABLE 18 US: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 48

TABLE 19 CANADA: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 49

TABLE 20 LATIN AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 50

TABLE 21 EUROPE: DULOXETINE API MARKET, BY REGION, 2022-2030 (USD MILLION) 52

TABLE 22 EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 52

TABLE 23 WESTERN EUROPE: DULOXETINE API MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 53

TABLE 24 WESTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 54

TABLE 25 GERMANY: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 55

TABLE 26 FRANCE: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 56

TABLE 27 UK: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 57

TABLE 28 ITALY: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 57

TABLE 29 SPAIN: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 58

TABLE 30 REST OF WESTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 59

TABLE 31 EASTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 60

TABLE 32 ASIA-PACIFIC: DULOXETINE API MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 62

TABLE 33 ASIA-PACIFIC: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 62

TABLE 34 CHINA: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 63

TABLE 35 INDIA: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 64

TABLE 36 JAPAN: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 65

TABLE 37 REST OF ASIA-PACIFIC: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 66

TABLE 38 MIDDLE EAST & AFRICA: DULOXETINE API MARKET, BY REGION, 2022-2030 (USD MILLION) 67

TABLE 39 MIDDLE EAST & AFRICA: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 68

TABLE 40 MIDDLE EAST: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 69

TABLE 41 AFRICA: DULOXETINE API MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 70

TABLE 42 GLOBAL DULOXETINE API MARKET, MARKET RANKING, 2022 71

12 List of Figures

FIGURE 1 MARKET SYNOPSIS 13

FIGURE 2 GLOBAL DULOXETINE API MARKET: MARKET STRUCTURE 14

FIGURE 3 RESEARCH PROCESS OF MRFR 15

FIGURE 4 TOP-DOWN & BOTTOM-UP APPROACH 18

FIGURE 5 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL DULOXETINE API MARKET 19

FIGURE 6 VALUE CHAIN: GLOBAL DULOXETINE API MARKET 23

FIGURE 7 PORTER’S FIVE FORCES ANALYSIS: GLOBAL DULOXETINE API MARKET 25

FIGURE 8 GLOBAL DULOXETINE API MARKET, BY APPLICATION, 2022 (%) 35

FIGURE 9 GLOBAL DULOXETINE API MARKET, BY APPLICATION, 2022 AND 2030 (USD MILLION) 35

FIGURE 10 GLOBAL DULOXETINE API MARKET, BY REGION, 2022 (%) 42

FIGURE 11 GLOBAL DULOXETINE API MARKET, BY REGION, 2022 AND 2030 (USD MILLION) 42

FIGURE 12 AMERICAS: DULOXETINE API MARKET, BY REGION, 2022 AND 2030 44

FIGURE 13 NORTH AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2022 AND 2030 46

FIGURE 14 EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2022 AND 2030 51

FIGURE 15 WESTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2022 AND 2030 53

FIGURE 16 ASIA-PACIFIC: DULOXETINE API MARKET, BY APPLICATION, 2022 AND 2030 61

FIGURE 17 MIDDLE EAST & AFRICA: DULOXETINE API MARKET, BY APPLICATION, 2022 AND 2030 67